Skip to main content
OpenTrials
Completed

NCT Number: NCT06322927

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.

Completed

Looking for future studies?

Notify Me

Key information

About this study

People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants with confirmed MM (per standard disease specific diagnostic criteria)
  • Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:
  • Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
  • Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.
  • Aged 18 years of age or over
  • Able to provide informed consent
  • Able to communicate in English

Exclusion criteria

  • Aged under 18
  • Unable to understand and communicate in the English language
  • Unable to provide written informed consent

Treatment and study plan

Patient interview

Other

Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.

Primary outcomes

  1. Patient Experience and Preference

    Time frame: 30-60 minutes

    The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.

Secondary outcomes

  1. Treatment and Preference Differences

    Time frame: 30-60 minutes

    The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments.

Sponsors and collaborators

Lead sponsor

The Christie NHS Foundation Trust

Other

Collaborators

  • CellCentric Ltd.

Registry information

Acronym: iPREFER

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 21, 2024
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.